Volume 64, Issue 3, Pages (March 2016)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Volume 50, Issue 3, Pages (March 2009)
Volume 46, Issue 3, Pages (March 2007)
Volume 65, Issue 1, Pages S2-S21 (October 2016)
Volume 58, Issue 1, Pages (January 2013)
Volume 50, Issue 4, Pages (April 2009)
Volume 67, Issue 2, Pages (August 2017)
Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”
Volume 44, Issue 2, Pages (February 2006)
Volume 145, Issue 4, Pages (October 2013)
Volume 141, Issue 2, Pages e3 (August 2011)
Volume 68, Issue 3, Pages (March 2018)
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Volume 65, Issue 4, Pages (October 2016)
Volume 42, Issue 1, Pages (January 2015)
Volume 63, Issue 4, Pages (October 2015)
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Volume 154, Issue 3, Pages e8 (February 2018)
Immigration and viral hepatitis
Volume 44, Issue 5, Pages (May 2006)
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Stephanos J. Hadziyannis  Journal of Hepatology 
Volume 125, Issue 1, Pages 9-18 (July 2003)
Volume 44, Issue 4, Pages (April 2006)
Volume 68, Issue 3, Pages (March 2018)
Volume 61, Issue 2, Pages (August 2014)
F. Li, P. Zhou, W. Deng, J. Wang, R. Mao, Y. Zhang, J. Li, J. Yu, F
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Volume 68, Issue 3, Pages (March 2018)
Volume 62, Issue 3, Pages (March 2015)
Volume 13, Issue 2, Pages (February 2006)
Volume 68, Issue 4, Pages (April 2018)
Volume 39, Issue 5, Pages (November 2003)
Therapeutic editing of hepatocyte genome in vivo
Volume 136, Issue 2, Pages e3 (February 2009)
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Volume 145, Issue 3, Pages e11 (September 2013)
Stephen Locarnini, Angelos Hatzakis, Ding-Shinn Chen, Anna Lok 
Volume 42, Issue 6, Pages (June 2005)
Volume 42, Issue 3, Pages (March 2005)
Volume 65, Issue 2, Pages (August 2016)
Volume 137, Issue 2, Pages (August 2009)
Volume 50, Issue 4, Pages (April 2009)
Fen Huang, Chenchen Yang, Xinying Zhou, Wenhai Yu, Qiuwei Pan 
Volume 58, Issue 1, Pages (January 2013)
Volume 128, Issue 3, Pages (March 2005)
Volume 56, Issue 6, Pages (June 2012)
Immigration and viral hepatitis
Volume 42, Issue 1, Pages (January 2005)
Induction of Angiopoietin-2 gene expression by COX-2: A novel role for COX-2 inhibitors during hepatocarcinogenesis  Shinji Tanaka, Jack R. Wands, Shigeki.
Serum HBV pgRNA as a clinical marker for cccDNA activity
Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection  Isabelle Chemin,
Volume 55, Issue 5, Pages (November 2011)
Volume 51, Issue 2, Pages (August 2009)
Volume 42, Issue 2, Pages (February 2005)
Chronic hepatitis B in children and adolescents
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Volume 116, Issue 3, Pages (March 1999)
Chimeric mouse model of hepatitis B virus infection
Volume 56, Issue 3, Pages (March 2012)
Effective Therapy Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer with Lung Metastasis  Yu Sakurai, Tomoya.
Molecular Therapy - Nucleic Acids
Volume 21, Issue 3, Pages (March 2017)
Volume 64, Issue 3, Pages (March 2016)
Role of Cell-Penetrating Peptides in Intracellular Delivery of Peptide Nucleic Acids Targeting Hepadnaviral Replication  Bénédicte Ndeboko, Narayan Ramamurthy,
Volume 53, Issue 4, Pages (October 2010)
Presentation transcript:

Volume 64, Issue 3, Pages 547-555 (March 2016) Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection  Naoki Yamamoto, Yusuke Sato, Tsubasa Munakata, Masakazu Kakuni, Chise Tateno, Takahiro Sanada, Yuichi Hirata, Shuko Murakami, Yasuhito Tanaka, Kazuaki Chayama, Hiroto Hatakeyama, Mamoru Hyodo, Hideyoshi Harashima, Michinori Kohara  Journal of Hepatology  Volume 64, Issue 3, Pages 547-555 (March 2016) DOI: 10.1016/j.jhep.2015.10.014 Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Development of a new pH-sensitive cationic lipid YSK13-C3 and characterization of MEND/siRNA. (A) Synthesis of YSK13-C3. Reagents; (i) 1, tert-butyl diethylphosphonoacetate, tBuOH, tBuOK; (ii) TFA/DCM 1/9; (iii) 3-(dimethylamino)-1-propanol, EDC, DMAP, DCM. (B) Dose-dependent F7 gene silencing activity of MEND/siF7 in normal mice. (C) Quantification of biodistribution of MEND/siRNA. Lipid membrane of MEND was labeled with DiD. (D) Observation of intrahepatic distribution of MEND/siRNA. Lipid membrane and siRNA were labeled with DiI and Cy5, respectively. Journal of Hepatology 2016 64, 547-555DOI: (10.1016/j.jhep.2015.10.014) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Selection of siRNA targeting HBV mRNAs. (A) Conservation of HBV sequences and target regions for siRNAs. The conservation rate of nucleotide sequences was calculated based on sequences from 16 strains (each genotype A, B, or C). Seven siRNA target sequences were selected from highly conserved regions. Numbering of HBV bases begins with position 1 at the EcoRI site. (B) Alignment of HBV sequences in siRNAs target regions. Dashed lines indicate identical nucleotides among siRNA target sequences. Journal of Hepatology 2016 64, 547-555DOI: (10.1016/j.jhep.2015.10.014) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Efficacy of MEND/HBV-siRNA containing a single siRNA in primary hepatocytes infected with HBV. (A) Experimental schedule for primary hepatocytes infected with HBV. (B) HBV DNA kinetics in the supernatant of primary hepatocytes inoculated with serum derived from HBV-infected mice. (C and D) Relative amounts of HBsAg and HBeAg. The supernatants (sup) from three independent experiments were pooled and analyzed. The mean value of each control siRNA was defined as the baseline. (E) Relative amount of HBV DNA. The mean values and standard deviations are shown based on the results of three independent experiments. The mean values for each control siRNA were defined as the baselines. Statistical comparison was performed using the t test. dpi, days post-infection. Journal of Hepatology 2016 64, 547-555DOI: (10.1016/j.jhep.2015.10.014) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Efficacy of MEND/HBV-siRNAmix containing the siRNAmix in vitro. (A) Experimental schedule for primary hepatocytes infected with HBV genotype C. (B) Relative amounts of HBsAg and HBeAg in the medium. (C and D) Relative amounts of extracellular and intracellular levels of HBV genomic DNA. The mean values and standard deviations are shown based on the results of three independent experiments. The mean values for non-treated (NT) were defined as the baselines. Statistical comparison was performed using the t test. dpi, days post-infection. Journal of Hepatology 2016 64, 547-555DOI: (10.1016/j.jhep.2015.10.014) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 5 Efficacy of MEND/HBV-siRNAmix in vivo. (A) Experimental schedule for chimeric mice with humanized liver. (B) Viral proliferation of a genotype C virus in chimeric mice. (C) Relative amounts of HBsAg and HBeAg in sera. (D) Relative amount of HBV DNA. (E) The amounts of human albumin (Alb) in sera. (F) Relative amounts of HBV DNA, HBsAg, and HBeAg in sera. Journal of Hepatology 2016 64, 547-555DOI: (10.1016/j.jhep.2015.10.014) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions